FBInvestor
Stocks / Inhibrx Biosciences Inc
Institutional Ownership

Inhibrx Biosciences Inc

CUSIP 45720N103COMINBXQ1 2026

13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
12.3%
Max % of class reported
Institutional Holders
128
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

12 filings · latest Feb 17, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 17, 2026Viking Global Investors LP13G/A10.0%1.45MSEC
2Feb 11, 2026Morgan Stanley13G7.9%1.16MSEC
3Jan 21, 2026Blackrock, Inc.13G5.3%768.1KSEC
4Oct 17, 2025Blackrock, Inc.13G/A4.7%680.4KSEC
5Feb 26, 2025The Jon F. Kayyem And Paige Gates-Kayyem Family Trust13D/A7.9%SEC
6Feb 26, 2025Mark Lappe13D/A6.4%SEC
7Feb 4, 2025Blackrock, Inc.13G5.7%831.8KSEC
8Nov 14, 2024Perceptive Advisors LLC13G9.9%1.49MSEC
9Jun 7, 2024Viking Global Investors LP13G12.3%1.79MSEC
10Jun 3, 2024Kayyem Jon Faiz13D5.6%806.1KSEC

2 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Inhibrx Biosciences Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Perceptive Advisors LLC1.44M$96.99M
2Viking Global Investors LP1.44M$96.66M
3Morgan Stanley1.26M$84.92M
4Sanofi1.16M$77.85M
5Hightower Advisors, LLC870.2K$58.50M
6Blackrock, Inc.798.9K$53.71M
7State Street Corp550.8K$37.03M
8Sofinnova Investments, Inc.406.0K$27.30M
9Capital Research Global Investors392.8K$26.41M
10Woodline Partners LP384.4K$25.85M